Literature DB >> 14690314

Cervical cancer staging.

Sergio Pecorelli1, Franco Odicino.   

Abstract

The "International Classification of the Stages of Carcinoma of the Uterine Cervix" dates back to 1950; since then, seven changes have been made to the staging system for cervical cancer (almost all were made to Stage I), the most recent being in 1995. The FIGO system of classification of cervical cancer is originally based on the results of clinical examination, essentially of the anatomical extent of disease, and is determined at the time of primary diagnosis. Only if the rules for clinical staging are strictly observed is it possible to compare results using different modalities of treatment. Cervical cancer remains a clinically staged malignancy according to the FIGO staging system. Surgical-pathologic staging would not be feasible for advanced-stage disease or in early-stage patients treated primarily with radiation, especially in nations that do not routinely offer surgical extirpation due to different or limited health care resources. However, surgical and pathological data are important for precise analysis of survival and prognostic risk factors.

Entities:  

Mesh:

Year:  2003        PMID: 14690314     DOI: 10.1097/00130404-200309000-00009

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  6 in total

1.  Prognostic significance of dysadherin expression in cervical squamous cell carcinoma.

Authors:  Dan Wu; Yuhuan Qiao; Gunnar B Kristensen; Shanshan Li; Gunhild Troen; Ruth Holm; Jahn M Nesland; Zhenhe Suo
Journal:  Pathol Oncol Res       Date:  2004-12-27       Impact factor: 3.201

2.  Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels.

Authors:  Xiugui Sheng; Xuelian Du; Xiaoling Zhang; Dapeng Li; Chunhua Lu; Qinshui Li; Zhifang Ma; Quqing Song; Cong Wang
Journal:  Croat Med J       Date:  2009-10       Impact factor: 1.351

Review 3.  Implications of the new FIGO staging and the role of imaging in cervical cancer.

Authors:  Aki Kido; Yuji Nakamoto
Journal:  Br J Radiol       Date:  2021-05-14       Impact factor: 3.629

4.  Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237.

Authors:  Yaman Tayyar; Ryan Shiels; Andrew C Bulmer; Alfred K Lam; Daniel Clarke; Adi Idris; Nigel A McMillan
Journal:  PLoS One       Date:  2019-11-27       Impact factor: 3.240

5.  Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma.

Authors:  Ruth Holm; Irene Kraus; Hanne Skomedal; Anita Langerød; Gunnar B Kristensen; Heidi Lyng
Journal:  Open Virol J       Date:  2008-10-24

6.  Expression of Nemo-like kinase in cervical squamous cell carcinoma: a clinicopathological study.

Authors:  Weina Yang; Lina Gu; Chang Yang; Tianbo Liu
Journal:  Onco Targets Ther       Date:  2018-02-08       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.